Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2918 • 2018 ACR/ARHP Annual Meeting
Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Lori Tucker¹, Jaime Guzman¹, Kristin Houghton², Dax G. Rumsey³, Elizabeth Stringer⁴, Shirley M.L. Tse⁵, Rosie Scuccimarri⁶, Claire LeBlanc⁷, Roberta Berard⁸, Bianca Lang⁹, Karen N Watanabe Duffy¹⁰ and Ciarán M. Duffy¹¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Rheumatology/Pediatrics, British Columbia Children's Hospital, Vancouver, BC, Canada, ³Stollery Children's Hospital, Edmonton, AB, Canada, ⁴Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, ⁷Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, ⁸Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁹Pediatrics, IWK Health Centre, Halifax, NS, Canada, ¹⁰Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Physical activity (PA) is an important component of health, and is essential for optimal growth and development. Children with juvenile idiopathic arthritis (JIA) are…
Abstract Number: 2018 • 2018 ACR/ARHP Annual Meeting
Microenvironment Driven Re-Shaping of Pathogenic T Effector and Regulatory Subset in Active Juvenile Idiopathic Arthritic Patients
Jing Yao Leong¹, Pavanish Kumar¹, Phyllis Chen², Joo Guan Yeo^2,3, Camillus Chua², Sharifah Nur Hazirah², Suzan Saidin¹, Thaschawee Arkachaisri^2,3, Alessandro Consolaro⁴, Marco Gattorno⁵, Alberto Martini⁶ and Salvatore Albani², ¹Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore, Singapore, ²Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore, ⁴Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genova, Italy, ⁵Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genoa, Italy, ⁶Pediatric Rheumatology International Trial Organization (PRINTO) Coordinating Centre, Genoa, Italy
Background/Purpose: We have previously identified two CD4 pathogenic circulatory subsets in both T effector (CPLs) and T regulatory (iaTreg) compartments that are both HLA-DR+, antigen…
Abstract Number: 2963 • 2018 ACR/ARHP Annual Meeting
Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis- a Quaternary Center Experience
Cagri Yildirim-Toruner¹, Ohoud AlAhmed², Fatima Barbar-Smiley³, Karla Jones³, Melanie Kohlheim⁴, Stephanie Lemle⁵, Darby MacDonald², Evan Mulvihill⁶, Edward Oberle², Aliese Sarkissian², Vidya Sivaraman⁷, Bethanne Thomas², Kelly Wise⁸ and Stacy P. Ardoin¹, ¹Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ²Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶Pediatrics and Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁷Division of Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁸Specialty Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatologic diagnosis, influences many aspects of a child’s life. Although there is no known cure, disease…
Abstract Number: 2027 • 2018 ACR/ARHP Annual Meeting
Whole Exome Trio Sequencing Implicates DOCK2 in Juvenile Idiopathic Arthritis
Laura A McIntosh^1,2, Yoshinori Fukui³, Thomas A. Griffin⁴, Kenneth Kaufman^1,2,5, Jarek Meller^6,7, Sherry Thornton⁸, Halima Moncrieffe^1,2 and Susan D Thompson^1,2, ¹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ³Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan, ⁴Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷Department of Environmental Health, University of Cincinnati, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and has a strong genetic component to disease risk. Genome-wide association studies…
Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Nicola Ruperto¹, Hermine I. Brunner², Gabriel Vega-Cornejo³, Alberto Berman⁴, Rubén J. Cuttica⁵, Francisco Ávila-Zapata⁶, Michael Henrickson⁷, Daniel J Kingsbury⁸, John F. Bohnsack⁹, Thomas Lutz¹⁰, Nadina E Rubio-Pérez¹¹, Valeria Gerloni¹², Xiaohui Li¹³, Marleen Nys¹⁴, Robert Wong¹³, Alberto Martini¹⁵ and Daniel J Lovell¹⁶, ¹Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁵Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁶Star Medica Hospital, Merida, Yucatán, Mexico, ⁷Cincinnati Children’s Medical Center, Cincinnati, OH, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹University of Utah School of Medicine, Salt Lake City, UT, ¹⁰Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, ¹¹Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, ¹²Istituto Gaetano Pini, Milan, Italy, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
Abstract Number: 2389 • 2018 ACR/ARHP Annual Meeting
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
Emily A. Smitherman¹, Bin Huang², Ronald M. Laxer³, C. April Bingham⁴, Cagri Yildirim-Toruner⁵, Beth Gottlieb⁶, Jennifer Weiss⁷, Tzielan Lee⁸, Sheetal S. Vora⁹, Jon (Sandy) Burnham¹⁰, Julia Harris¹¹, Judyann C. Olson¹², Mileka Gilbert¹³, Michelle Batthish¹⁴, Michael Shishov¹⁵, Dustin Fleck¹⁶ and Esi Morgan¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Health Children's Hospital, Hershey, PA, ⁵Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁶Pediatric Rheumatology PTD, Cohen Children's Medical Center of New York, Lake Success, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁹Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ¹⁰Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹Children's Mercy - Kansas City, Kansas City, MO, ¹²Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁵Phoenix Children's Hospital, Phoenix, AZ, ¹⁶Pediatric Rheumatology, University of Michigan, Brighton, MI
Background/Purpose: It is widely accepted that the treatment goal for juvenile idiopathic arthritis (JIA) is remission. PR-COIN, a quality improvement collaborative comprised of pediatric rheumatology…
Abstract Number: 2391 • 2018 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients
Nami Okamoto¹, Kosuke Shabana², Yasuo Nakagishi³, Kenichi Nishimura⁴, Mao Mizuta⁵, Yuka Okura⁶, Masaki Shimizu⁵, Hiroyuki Wakiguchi⁷, Junko Yasumura⁸ and Masaaki Mori⁹, ¹Pediatrics, Osaka Medical College, Takatsuki, Japan, ²Department of Pediatrics, Osaka Medical College, Takatsuki, Japan, ³Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, ⁴Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ⁶Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan, ⁷Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan, ⁸Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, ⁹Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Since MTX metabolism varies depending on age and dosage, we need to know optimal MTX administration method in children. We performed multi-center prospective study…
Abstract Number: 2396 • 2018 ACR/ARHP Annual Meeting
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Lisa Marshall⁴ and Heather Jones⁴, ¹Memorial University of Newfoundland, St John's, NF, Canada, ²IQVIA, Kanata, ON, Canada, ³Global Outcomes & Evidence, Pfizer, Collegeville, PA, ⁴Pfizer, Collegeville, PA
Background/Purpose: In Canada, the pediatric indications of etanercept (ETN) are active ankylosing spondylitis (AS), plaque psoriasis (PsO) and moderate to severely active juvenile idiopathic arthritis…
Abstract Number: 2398 • 2018 ACR/ARHP Annual Meeting
Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category
Dax G. Rumsey¹, Jaime Guzman², Alan Rosenberg³, Adam Huber⁴, Rosie Scuccimarri⁵, Natalie J. Shiff⁶, Alessandra Bruns⁷, Brian M. Feldman⁸ and Dean Eurich⁹, ¹Paediatrics, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, ⁶University of Florida, Gainesville, FL, ⁷Hospitalier de l’Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada
Background/Purpose: To estimate the impact of enthesitis on patient reported outcomes (PROs) in children with juvenile idiopathic arthritis (JIA), irrespective of their JIA category. Methods:…
Abstract Number: 2400 • 2018 ACR/ARHP Annual Meeting
Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population
Tristan Scheer¹, Jens Klotsche², Claudio A. Len³ and Ivan Foeldvari⁴, ¹Asklepios Campus Hamburg, Semmelweis University Budapest, Hamburg, Germany, ²Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo,, Brazil, ⁴Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatologic disease in children and adolescents with a prevalence of 1:1000 children in Germany.…
Abstract Number: 2403 • 2018 ACR/ARHP Annual Meeting
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
Valérie Devauchelle-Pensec¹, Anne Lohse², Francis Guillemin³, Elisabeth Solau-Gervais⁴, Linda Rossi-Semerano⁵, Agnès Duquesne⁶, Irène Lemelle⁷, Pascal Pillet⁸, Claire Ballot⁹, Laurence Goumy¹⁰, Tu Anh Tran¹¹, Laeticia Sparsa¹², Heloise Reumaux¹³, Anaïs Arbault¹⁴ and Camille Alleyrat¹⁵, ¹Rheumatology, CHU Brest, Brest, France, ²Rheumatology Department, Hopital Nord Franche Comté, Belfort, France, ³Université de Lorraine, EA4360, APEMAC, Nancy, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁶4Department of Nephrology-Rheumatology-Dermatology Pediatric - Rheumatology, Hopital Femme-Mère-Enfant, Bron, France, ⁷Department of pediatric onco-hematology, CHU de Nancy - Hôpitaux de Brabois,, Vandœuvre-Lès-Nancy, France, ⁸Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, ⁹Department of Pediatric Rheumatology, Hôpital Jean-Minjoz, Besançon, France, ¹⁰Pediatric, CHU d'Angers, Angers, France, ¹¹Paediatrics, University Hospital, Nîmes, Nîmes, France, ¹²Rheumatology, Hopital Emile Muller, Mulhouse, France, ¹³Pediatric Rheumatology, CHRU Lille, Lille, France, ¹⁴Rheumatology, CHU de Dijon, Dijon, France, ¹⁵134 Inserm CIC-1433 Clinical Epidemiology, CHRU de Nancy, Hôpitaux de Brabois, Nancy, France
Background/Purpose: The therapeutic compliance (TC) is a major issue for the management of Juvenile Idiopathic Arthritis (JIA). The chronic nature of this inflammatory rheumatism requires…
Abstract Number: 2404 • 2018 ACR/ARHP Annual Meeting
Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment
W. Blaine Lapin¹, Taylor Phillips², Danielle Guttman-Lapin³, Amanda Brown⁴, Eyal Muscal⁵ and Filiz O. Seeborg¹, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Rice University, Houston, TX, ³Aldine Independent School District, Aldine, TX, ⁴Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Baylor College of Medicine, houston, TX, ⁵Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Patients with Juvenile Idiopathic Arthritis (JIA) face physical, social, and emotional issues that affect their quality of life. Health-related quality of life (HRQoL) is…
Abstract Number: 2405 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
Joseph McDonald¹, Curtis Travers², Courtney McCracken², Steven Yeh³, Kelly A. Rouster-Stevens⁴, Patricia Vega-Fernandez⁴, Elaine Ramsay⁴, Sampath Prahalad⁴, Carolyn Drews-Botsch⁵ and Sheila Angeles-Han⁶, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁶Rheumatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH
Background/Purpose: Pediatric chronic non-infectious uveitis can lead to ocular complications and vision loss. The ophthalmic clinical exam is primarily used to assess uveitis outcomes but…
Abstract Number: 2407 • 2018 ACR/ARHP Annual Meeting
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Mikhail Kostik, Ekaterina Gaidar, Maria Likhacheva, Eugenia Isupova, Irina Chikova, Margarita Dubko, Vera Masalova, Tatiana Likhacheva, Ludmila Snegireva, Tatiana Kornishina, Olga Kalashnikova and Vyacheslav Chasnyk, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The most often prescribed biologics…
Abstract Number: 2409 • 2018 ACR/ARHP Annual Meeting
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
Guillaume Montagu¹, Ellie Mevel¹, William FAHY², Linda Rossi-Semerano³, Elisabeth Solau-Gervais⁴, Sonia Tropé⁵ and Jean-David Cohen⁶, ¹Research, Unknowns, strategy and innovation consulting, PARIS, France, ²KOURIR, Paris, France, ³Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵149 avenue du Maine, ANDAR, Paris, France, ⁶IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France
Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].